Epstein Files Search

larger opportunity). Of note, no therapies arc approved for active Carter L Gould RSV; Synagis is approved as a prophylaxis in a narrow segment of infants and very few assets ... children, RSV treatment guidelines issued by the American Academy of Pediatrics only recommends Synagis specifically for prophylaxis in an increasingly narrow segment of infants. Additionally, the guidelines caution that supportive ... 375M. Assuming an US/OUS market split of 65/35 (relatively in•line with existing Synagis trends; $975M WW with $570M in the US), we forecast a WW opportunity at peak